| TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma (NCT07507968) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2026-07-01 |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab (NCT07387198) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2026-05-29 |
| Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept (NCT07542678) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2026-04-01 |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients (NCT07176312) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2026-01-16 |
| Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab (NCT07510724) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-23 |
| NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy (NCT07365930) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-17 |
| DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma (NCT07110038) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-16 |
| Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities (NCT06722183) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-16 |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma (NCT07059299) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-12-12 |
| Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma (NCT07260175) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-11-18 |
| - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (NCT06856837) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-10-27 |
| Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients (NCT06981325) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-08-07 |
| Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (NCT06731803) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-03-25 |
| Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy (NCT06680622) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-03-03 |
| Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma (NCT06440993) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2024-08-23 |
| Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (NCT06178445) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2024-04-17 |
| Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (NCT06123468) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2024-04-17 |
| Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer (NCT06207734) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2024-01-17 |
| Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients (NCT06050434) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2023-10-31 |
| Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery (NCT05713838) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2023-08-28 |
| NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing (NCT05825625) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2023-05-26 |
| Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP (NCT05798156) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2023-03-20 |
| Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma (NCT05504720) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2023-02-13 |
| Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements (NCT05565794) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-11-11 |
| Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma (NCT05268510) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-09-15 |
| New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC) (NCT04896931) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-07-12 |
| Fedratinib in Combination With Nivolumab (NCT05393674) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-06-14 |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer (NCT05239169) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-05-23 |
| Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy (NCT05101629) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-05-11 |
| Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements (NCT05174650) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2022-04-20 |
| Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (NCT05080790) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2021-11-15 |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma (NCT04803994) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2021-07-06 |
| Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC (NCT04522544) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-12-15 |
| Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment (NCT04511455) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-12-08 |
| PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) (NCT04484636) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-28 |
| The PLATON Network (NCT05489250) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-28 |
| Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (NCT04517747) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-15 |
| Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function (NCT04522908) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-10-12 |
| Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (NCT04462276) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-07-28 |
| Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (NCT04351256) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-05-20 |
| Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping (NCT04318938) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-03-30 |
| Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS) (NCT04105777) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-01-30 |
| Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) (NCT04238637) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-11-01 |
| PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (NCT04119362) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-10-24 |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma (NCT03841201) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-06-12 |
| IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (NCT03753659) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-05-09 |
| Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy (NCT03762564) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-03-08 |
| CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study (NCT04147143) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-03-08 |
| Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery (NCT04177953) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-02-04 |
| RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (NCT03520946) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-01-24 |
| GISAR German Interdisciplinary Sarcoma Registry (NCT04122872) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-11-29 |
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients (NCT03698227) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-11-12 |
| Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (NCT03647969) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-11-07 |
| Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (NCT03530267) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-09-28 |
| Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (NCT03421288) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-09-14 |
| Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma" (NCT05222854) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2017-10-11 |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (NCT03252938) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2017-08-15 |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (NCT03081143) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2017-05-10 |
| FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (NCT02661971) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2016-06-01 |
| FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (NCT02581462) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2016-06-01 |
| Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. (NCT02469480) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2015-03-01 |
| Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program (NCT02691052) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2014-12-01 |
| Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer (NCT01956149) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2013-09-01 |